Logo image of ABCM

ABCAM PLC-SPON ADR (ABCM) Stock Fundamental Analysis

NASDAQ:ABCM - Nasdaq - US0003802040 - ADR - Currency: USD

23.99  +0.01 (+0.04%)

After market: 23.99 0 (0%)

Fundamental Rating

5

Overall ABCM gets a fundamental rating of 5 out of 10. We evaluated ABCM against 557 industry peers in the Biotechnology industry. ABCM has an average financial health and profitability rating. ABCM is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year ABCM was profitable.
In the past year ABCM had a positive cash flow from operations.
ABCM Yearly Net Income VS EBIT VS OCF VS FCFABCM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

1.2 Ratios

The Return On Assets of ABCM (0.64%) is better than 93.86% of its industry peers.
Looking at the Return On Equity, with a value of 0.93%, ABCM belongs to the top of the industry, outperforming 93.86% of the companies in the same industry.
ABCM has a better Return On Invested Capital (1.98%) than 94.69% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ABCM is significantly below the industry average of 14.78%.
The 3 year average ROIC (6.00%) for ABCM is well above the current ROIC(1.98%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 0.64%
ROE 0.93%
ROIC 1.98%
ROA(3y)4.53%
ROA(5y)8.06%
ROE(3y)5.58%
ROE(5y)9.64%
ROIC(3y)6%
ROIC(5y)8.74%
ABCM Yearly ROA, ROE, ROICABCM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 5 10 15

1.3 Margins

ABCM has a Profit Margin of 1.94%. This is amongst the best in the industry. ABCM outperforms 94.86% of its industry peers.
ABCM's Profit Margin has declined in the last couple of years.
ABCM has a Operating Margin of 8.70%. This is amongst the best in the industry. ABCM outperforms 95.36% of its industry peers.
ABCM's Operating Margin has declined in the last couple of years.
The Gross Margin of ABCM (72.69%) is better than 83.58% of its industry peers.
ABCM's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 8.7%
PM (TTM) 1.94%
GM 72.69%
OM growth 3Y-28.84%
OM growth 5Y-15.57%
PM growth 3Y-41.13%
PM growth 5Y-24.24%
GM growth 3Y0.59%
GM growth 5Y0.27%
ABCM Yearly Profit, Operating, Gross MarginsABCM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 20 40 60

More info and screens

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ABCM is destroying value.
The number of shares outstanding for ABCM has been increased compared to 1 year ago.
The debt/assets ratio for ABCM has been reduced compared to a year ago.
ABCM Yearly Shares OutstandingABCM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M
ABCM Yearly Total Debt VS Total AssetsABCM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M 800M

2.2 Solvency

ABCM has an Altman-Z score of 8.64. This indicates that ABCM is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.64, ABCM belongs to the top of the industry, outperforming 85.41% of the companies in the same industry.
ABCM has a debt to FCF ratio of 19.99. This is a negative value and a sign of low solvency as ABCM would need 19.99 years to pay back of all of its debts.
ABCM has a better Debt to FCF ratio (19.99) than 94.03% of its industry peers.
A Debt/Equity ratio of 0.30 indicates that ABCM is not too dependend on debt financing.
ABCM has a Debt to Equity ratio of 0.30. This is in the lower half of the industry: ABCM underperforms 71.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF 19.99
Altman-Z 8.64
ROIC/WACC0.22
WACC8.89%
ABCM Yearly LT Debt VS Equity VS FCFABCM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M

2.3 Liquidity

A Current Ratio of 1.26 indicates that ABCM should not have too much problems paying its short term obligations.
With a Current ratio value of 1.26, ABCM is not doing good in the industry: 86.73% of the companies in the same industry are doing better.
ABCM has a Quick Ratio of 1.26. This is a bad value and indicates that ABCM is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ABCM (0.98) is worse than 88.56% of its industry peers.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 0.98
ABCM Yearly Current Assets VS Current LiabilitesABCM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

ABCM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 402.64%, which is quite impressive.
ABCM shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -17.30% yearly.
ABCM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.70%.
Measured over the past years, ABCM shows a quite strong growth in Revenue. The Revenue has been growing by 11.64% on average per year.
EPS 1Y (TTM)402.64%
EPS 3Y-38.1%
EPS 5Y-17.3%
EPS Q2Q%191.67%
Revenue 1Y (TTM)17.7%
Revenue growth 3Y8.48%
Revenue growth 5Y11.64%
Sales Q2Q%23.3%

3.2 Future

Based on estimates for the next years, ABCM will show a very strong growth in Earnings Per Share. The EPS will grow by 40.12% on average per year.
Based on estimates for the next years, ABCM will show a quite strong growth in Revenue. The Revenue will grow by 11.28% on average per year.
EPS Next Y125.95%
EPS Next 2Y68.04%
EPS Next 3Y52.49%
EPS Next 5Y40.12%
Revenue Next Year24.37%
Revenue Next 2Y18.92%
Revenue Next 3Y16.75%
Revenue Next 5Y11.28%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ABCM Yearly Revenue VS EstimatesABCM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M 400M 500M
ABCM Yearly EPS VS EstimatesABCM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 44.43 indicates a quite expensive valuation of ABCM.
94.69% of the companies in the same industry are more expensive than ABCM, based on the Price/Earnings ratio.
ABCM's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.32.
ABCM is valuated quite expensively with a Price/Forward Earnings ratio of 49.32.
Based on the Price/Forward Earnings ratio, ABCM is valued cheaply inside the industry as 94.53% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of ABCM to the average of the S&P500 Index (22.19), we can say ABCM is valued expensively.
Industry RankSector Rank
PE 44.43
Fwd PE 49.32
ABCM Price Earnings VS Forward Price EarningsABCM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ABCM is valued cheaply inside the industry as 94.20% of the companies are valued more expensively.
93.86% of the companies in the same industry are more expensive than ABCM, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 374.67
EV/EBITDA 55.61
ABCM Per share dataABCM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of ABCM may justify a higher PE ratio.
ABCM's earnings are expected to grow with 52.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.35
PEG (5Y)N/A
EPS Next 2Y68.04%
EPS Next 3Y52.49%

More info and screens

0

5. Dividend

5.1 Amount

ABCM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABCAM PLC-SPON ADR

NASDAQ:ABCM (12/5/2023, 8:00:00 PM)

After market: 23.99 0 (0%)

23.99

+0.01 (+0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-12 2022-09-12/dmh
Earnings (Next)N/A N/A
Inst Owners1.79%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap5.49B
Analysts80
Price Target20.23 (-15.67%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 44.43
Fwd PE 49.32
P/S 12.3
P/FCF 374.67
P/OCF 79.64
P/B 5.92
P/tB 42.37
EV/EBITDA 55.61
EPS(TTM)0.54
EY2.25%
EPS(NY)0.49
Fwd EY2.03%
FCF(TTM)0.06
FCFY0.27%
OCF(TTM)0.3
OCFY1.26%
SpS1.95
BVpS4.05
TBVpS0.57
PEG (NY)0.35
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.64%
ROE 0.93%
ROCE 3.54%
ROIC 1.98%
ROICexc 2.23%
ROICexgc 7.95%
OM 8.7%
PM (TTM) 1.94%
GM 72.69%
FCFM 3.28%
ROA(3y)4.53%
ROA(5y)8.06%
ROE(3y)5.58%
ROE(5y)9.64%
ROIC(3y)6%
ROIC(5y)8.74%
ROICexc(3y)7.76%
ROICexc(5y)11.54%
ROICexgc(3y)24.8%
ROICexgc(5y)47.7%
ROCE(3y)9.88%
ROCE(5y)14%
ROICexcg growth 3Y-57.08%
ROICexcg growth 5Y-37.19%
ROICexc growth 3Y-42.21%
ROICexc growth 5Y-23.94%
OM growth 3Y-28.84%
OM growth 5Y-15.57%
PM growth 3Y-41.13%
PM growth 5Y-24.24%
GM growth 3Y0.59%
GM growth 5Y0.27%
F-Score5
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF 19.99
Debt/EBITDA 2.79
Cap/Depr 90.64%
Cap/Sales 12.16%
Interest Coverage 9.53
Cash Conversion 69.81%
Profit Quality 169.12%
Current Ratio 1.26
Quick Ratio 0.98
Altman-Z 8.64
F-Score5
WACC8.89%
ROIC/WACC0.22
Cap/Depr(3y)181.11%
Cap/Depr(5y)191.67%
Cap/Sales(3y)16.16%
Cap/Sales(5y)14.67%
Profit Quality(3y)125.12%
Profit Quality(5y)105.69%
High Growth Momentum
Growth
EPS 1Y (TTM)402.64%
EPS 3Y-38.1%
EPS 5Y-17.3%
EPS Q2Q%191.67%
EPS Next Y125.95%
EPS Next 2Y68.04%
EPS Next 3Y52.49%
EPS Next 5Y40.12%
Revenue 1Y (TTM)17.7%
Revenue growth 3Y8.48%
Revenue growth 5Y11.64%
Sales Q2Q%23.3%
Revenue Next Year24.37%
Revenue Next 2Y18.92%
Revenue Next 3Y16.75%
Revenue Next 5Y11.28%
EBIT growth 1Y-18.45%
EBIT growth 3Y-22.8%
EBIT growth 5Y-5.74%
EBIT Next Year197.84%
EBIT Next 3Y63.16%
EBIT Next 5Y39.34%
FCF growth 1Y-42.5%
FCF growth 3Y-17.2%
FCF growth 5Y-14.26%
OCF growth 1Y66.98%
OCF growth 3Y4.34%
OCF growth 5Y8.73%